F&O Stocks to Buy: CDSL, Zydus Lifesciences and Sun Pharma on Jay Thakkar’s Near-Term List, With Price Levels, Technicals and Risks

F&O stocks to buy are stocks that trade in the futures and options segment and are picked for a near-term move, so the price levels and risk matter more than the story. This article shows the F&O stocks to buy named by Jay Thakkar, the price and technical data for each, the fundamentals and the risks of trading them in a market that fell as much as 1.1% this morning.

I could not find the full report, so I do not have his entry zones, targets or stop losses, and I have not made any up. The levels below come from the data provider’s indicators and are not his levels. Lot sizes and expiry details are also not covered. It is educational and not advice.

Click Here – Get Free Investment Predictions

F&O Stocks to Buy: Price and Technical Snapshot

F&O stocks to buy: stock	NSE price (11:26 AM)	RSI (14)	20-day EMA	Supertrend (10, 3)
CDSL	Rs 1,223.60, up 0.13%	37.7	Rs 1,249.03	Down; resistance Rs 1,280.73; lower band Rs 1,124.14
Zydus Lifesciences	Rs 1,177.60, up 0.4%	56.5	Rs 1,153.21	Up; support Rs 1,068.48; upper band Rs 1,207.32
Sun Pharma	Rs 1,746.90, down 0.25%	38.1	Rs 1,769.12	Up; support Rs 1,660.69; upper band Rs 1,838.61

Among these F&O stocks to buy, Zydus is the strongest of the three, above its 20-day average with a rising Supertrend. Sun Pharma is below its 20-day average but above its Supertrend support, and CDSL is below its average in a downtrend. The common factor is that none is near an extreme, since all RSI readings are between 37 and 57.

Track F&O stocks and set price alerts on Univest

Why Range-Bound Markets Matter for F&O Stocks to Buy

In the screenshot summary, Jay Thakkar said that markets may stay range-bound ahead of key events and identified support and resistance levels for the Nifty 50 and Bank Nifty. The key events this week are the US Fed decision, the Q2 results season and the Reliance and Jio results on 30 Oct. In a range-bound market, stock-specific picks such as these F&O stocks to buy can work better than index trades, but they can also reverse quickly if the index breaks out. This morning the Sensex was down as much as 995 points on crude above USD 115 and the Nifty touched 22,497, so the range is already being tested.

F&O stocks to buy: market reading	Level or fact	Note
Nifty 50 close, 27 Oct	22,749.75	Slightly lower on the day
Nifty 50 morning low, 28 Oct	22,497	Down about 1.1%
Sectors positive in the morning	Nifty Auto and Nifty Pharma	Pharma stocks held up better
Brent crude	About USD 115.5 to USD 115.9	Cost and inflation worry

Pharma was one of only two positive sectors this morning, which fits with Zydus and Sun Pharma being among the F&O stocks to buy. The Nifty IT index fell about 3.5%, so sector choice is doing some of the work.

CDSL Share Price and Fundamentals

F&O stocks to buy: CDSL metric	Reading	Note
Market capitalisation	About Rs 25,540 crore	Provider figure at the previous close
Price to earnings	About 54 times	Industry about 41.6 times
Return on equity	23.27%	Strong
Debt to equity	0.00	No debt
Dividend yield	About 1%	Provider figure
Q1 FY27 revenue and profit	Rs 340.50 crore and Rs 117.67 crore	Profit up about 14.9% from Rs 102.40 crore (my calculation)
Q1 FY27 operating margin	63.5%	Very high margin business

CDSL is a depository, so its revenue depends on market activity such as new accounts, transactions and issues. It earns very high margins and carries no debt, but at about 54 times earnings it is priced for growth. Its Supertrend is down, so the near-term trend is weak despite the pick. I did not find the CDSL Q2 results date. Among the F&O stocks to buy, CDSL is the one where the pick and the trend disagree, and the CDSL share price is tied to market activity.

Download the Univest iOS App or Univest Android App to set price alerts on CDSL and other F&O stocks.

Zydus Lifesciences Share Price and Fundamentals

F&O stocks to buy: Zydus metric	Reading	Note
Market capitalisation	About Rs 1,16,409 crore	Provider figure at the previous close
Price to earnings	About 25.4 times	Industry about 36.2 times
Return on equity	18.59%	Healthy
Debt to equity	0.46	Moderate
Q1 FY27 revenue	Rs 8,123.10 crore	Up about 20.7% from Rs 6,728.60 crore (my calculation)
Q1 FY27 net profit	Rs 952.40 crore	Down about 36% from Rs 1,486.60 crore (my calculation)
Q1 FY27 operating margin	25.86%	Down from 34.69% a year earlier

Zydus has growing revenue but a lower margin and profit than a year ago, and that is the key question for the stock. The valuation is below the industry, and the technical trend is up, so the market may be looking through the weaker margin. The Q2 results date was not available in the sources. That mix makes Zydus the most debated of the F&O stocks to buy.

Sun Pharma Share Price and Fundamentals

F&O stocks to buy: Sun Pharma metric	Reading	Note
Market capitalisation	About Rs 4,22,283 crore	Provider figure at the previous close
Price to earnings	About 34.9 times	Industry about 36.2 times
Return on equity	13.74%	Moderate
Debt to equity	0.06	Almost debt free
Q1 FY27 revenue	Rs 16,023.50 crore	Up about 11.9% from Rs 14,315.86 crore (my calculation)
Q1 FY27 net profit	Rs 2,910.80 crore	Up about 26.4% from Rs 2,302.62 crore (my calculation)
Q1 FY27 operating margin	32.52%	Up from 28.64% a year earlier

Sun Pharma has the most consistent profile of the three, with growing revenue, a higher margin and almost no debt, and its multiple is close to the industry average. The Sun Pharma share price is below the 20-day average of Rs 1,769.12, which shows a short-term pause inside a rising Supertrend. Of the F&O stocks to buy here, Sun Pharma has the most consistent fundamentals, and a move back above the average would help the Sun Pharma share price recover the short-term trend.

Risks When Trading F&O Stocks to Buy

1. Margin-funded risk. Positions in F&O stocks to buy are taken on margin, so a small price move can cause a large loss relative to capital.
2. Missing levels. The analyst’s entry, target and stop loss for these F&O stocks to buy were not retrieved, so any trade needs your own levels.
3. Market weakness. The Sensex fell as much as 995 points this morning, and a break of the range can reverse stock-specific picks.
4. Event risk. The Fed decision, results and crude oil can gap the market in either direction.
5. Stock-specific issues. The CDSL share price is in a downtrend, Zydus profit fell in Q1 and CDSL trades at about 54 times earnings.

Conclusion: F&O Stocks to Buy Need Defined Risk

The F&O stocks to buy on Jay Thakkar’s list, CDSL, Zydus Lifesciences and Sun Pharma, come with a view that markets stay range-bound, and the data shows Zydus and Sun Pharma with a rising Supertrend and CDSL in a downtrend. Without his levels, treat these F&O stocks to buy as a data check and not a trade plan. Set a stop loss, size the position to your own risk profile and verify any levels with the original report.

Frequently Asked Questions

Which F&O stocks to buy did Jay Thakkar name?

Ans. The headline names CDSL, Zydus Lifesciences and Sun Pharma as near-term F&O stocks to buy by ICICI Securities’ Jay Thakkar. I could not retrieve his entry zones, targets or stop losses.

What is Jay Thakkar’s view on the market?

Ans. He said markets may stay range-bound ahead of key events after the Sensex and Nifty ended slightly lower on Tuesday amid elevated oil prices and geopolitical uncertainty, and he identified support and resistance levels for the Nifty 50 and Bank Nifty, which I could not retrieve. His list of F&O stocks to buy sits inside this view.

What are the CDSL share price and technicals?

Ans. CDSL was Rs 1,223.60 on the NSE at 11:26 AM, with an RSI of 37.7, a 20-day EMA of Rs 1,249.03 and a Supertrend downtrend with resistance at Rs 1,280.73. The trailing price to earnings is about 54 times.

What are the Zydus Lifesciences share price and technicals?

Ans. Zydus was Rs 1,177.60, with an RSI of 56.5, a 20-day EMA of Rs 1,153.21 and a rising Supertrend with support at Rs 1,068.48. Q1 FY27 profit fell about 36% while revenue rose about 20.7%.

What are the Sun Pharma share price and technicals?

Ans. Sun Pharma was Rs 1,746.90, with an RSI of 38.1, a 20-day EMA of Rs 1,769.12 and a rising Supertrend with support at Rs 1,660.69. Q1 FY27 profit rose about 26.4% and the price to earnings is about 34.9 times. Of these F&O stocks to buy, it has the steadiest growth.

Where can I find the original report with the levels?

Ans. The original ICICI Securities note by Jay Thakkar would carry the entry zones, targets and stop losses. I could not retrieve it, so please check the broker’s research page or the news report before using any level for these F&O stocks to buy.

Are F&O stocks to buy safe for beginners?

Ans. No. Futures and options are margin-based, so losses can exceed expectations. Beginners should understand the contracts, position size and stop losses first, and nothing here is advice.

Is this article investment advice?

Ans. No. It is educational and not a recommendation to buy or sell. Please check the figures against company filings and your own risk profile before you act on anything you read here.